カテゴリ： GlobalData, アメリカ, 企業調査

Sunovion Pharmaceuticals Inc：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Sunovion Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C3430
◆発行会社（調査会社）：GlobalData
◆発行日：2018年8月
◆ページ数：62
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Sunovion Pharmaceuticals Inc (Sunovion), a subsidiary of Sumitomo Dainippon Pharma Co Ltd, is a research-based pharmaceutical company. It discovers, develops and commercializes therapeutic products that focus on the treatment of central nervous system and respiratory disorders. Its product portfolio includes eslicarbazepine acetate tablets, lurasidone HCl tablets, eszopiclone tablets, levalbuterol HCl inhalation solution, levalbuterol tartrate inhalation aerosol, arformoterol tartrate inhalation solution, ciclesonide nasal spray, ciclesonide inhalation aerosol and ciclesonide nasal aerosol. The existing product portfolio and the pipeline candidates are targeted for treating patients of epilepsy, anxiety, depression, asthma, pain, allergic rhinitis and chronic obstructive pulmonary diseases. Sunovion’s major customers include medical institutions, hospitals and general public. Sunovion is headquartered in Marlborough, Massachusetts, the US.

Sunovion Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sunovion Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Matrizyme Pharma Raises USD9 Million in Financing 13
Elevation Pharma Secures US$30 Million In Series B Financing 14
Private Equity 16
Orbimed Advisors Acquires Additional 3.17% Stake in Cynapsus Therapeutics for USD6.3 Million 16
Partnerships 17
ex scientia Enters into Research Agreement with Sunovion Pharma 17
Sunovion Pharma Enters Into Agreement With Afraxis To Discover CNS Drugs 18
PsychoGenics Extends Drug Discovery Agreement with Sunovion Pharma 19
Prasco Labs Enters into Distribution Agreement with Sunovion Pharma for Xopenex 20
Licensing Agreements 21
Angelini Enters into Licensing and Distribution Agreement with Sunovion Pharma 21
Sunovion Pharma Enters into Licensing Agreement with Novartis 22
Cynapsus Therapeutics Enters into Licensing Agreement with MonoSol Rx 23
Equity Offering 24
Cynapsus Therapeutics Raises USD72.5 Million in Public Offering of Shares 24
Cynapsus Therapeutics Raises USD16.6 Million in Private Placement of Shares 26
Cynapsus Therapeutics Completes Public Offering Of Units For US$22.8 Million 28
Cynapsus Therapeutics Completes Second Tranche Of Private Placement Of Units For US$1.3 Million 29
Cynapsus Therapeutics Completes Private Placement Of Units For US$1 Million 31
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.2 Million 32
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.1 Million 33
Debt Offering 34
Cynapsus Therapeutics Completes Additional Public Offering Of Series E Debentures Due 2013 For US$1.1 Million 34
Asset Transactions 36
Sunovion Pharma to Divest US Rights of Ciclesonide Products to Covis Pharma 36
Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 37
Acquisition 38
Sunovion Pharma Acquires Cynapsus Therapeutics for up to USD635 Million 38
Sunovion Pharma Completes Acquisition Of Elevation Pharma For Up To US$430 Million 40
Sunovion Pharmaceuticals Inc – Key Competitors 42
Sunovion Pharmaceuticals Inc – Key Employees 43
Sunovion Pharmaceuticals Inc – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Recent Developments 45
Product News 45
09/14/2017: Sunovion to Present Data on Dasotraline at the 2017 Psych Congress 45
05/23/2017: Sunovion Announces Positive Results from Pivotal Study Evaluating Novel Drug Candidate Dasotraline in Adults with Binge Eating Disorder at Annual American Psychiatric Association Meeting 46
05/16/2017: Sunovion to Present Data on Dasotraline at Annual American Psychiatric Association Meeting Showcase 48
05/02/2018: Sunovion to Present Data on dasotraline at the 2018 American Psychiatric Association Annual Meeting 49
01/14/2017: Sunovion Announces Pivotal Study Results for Novel Drug Candidate Dasotraline Demonstrating Significantly Improved Attention Deficit Hyperactivity Disorder Symptoms in Children Compared to Placebo 50
Product Approvals 51
Mar 30, 2018: Sunovion Submits New Drug Application to the FDA for Apomorphine Sublingual Film (APL-130277) for the Treatment of OFF Episodes Associated with Parkinson’s Disease 51
Nov 10, 2017: Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Treatment of ADHD 52
Aug 31, 2017: Sunovion Submits New Drug Application for Dasotraline to the FDA for the Treatment of Patients with ADHD 53
Jun 12, 2017: PsychoGenics Achieves a Milestone in Drug Discovery Collaboration with Sunovion 54
Clinical Trials 55
Jan 29, 2018: Sunovion Announces Positive Topline Results from Pivotal Study of Apomorphine Sublingual Film (APL-130277) in Patients with Parkinson’s Disease 55
Apr 21, 2017: Sunovion Announces Positive Results from Pivotal Study Evaluating Novel Drug Candidate Dasotraline in Children with ADHD 57
Apr 12, 2017: Sumitomo Dainippon Pharma Announces Positive Topline Results from a Phase 3 Study of Novel Drug Candidate Dasotraline Being Evaluated in the Treatment of Children with Attention Deficit Hyperactivity Disorder 59
Jan 13, 2017: Sunovion Announces Top-line Results from Studies Evaluating Dasotraline in Adults with Binge Eating Disorder and Attention Deficit Hyperactivity Disorder 60
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sunovion Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Sunovion Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Matrizyme Pharma Raises USD9 Million in Financing 13
Elevation Pharma Secures US$30 Million In Series B Financing 14
Orbimed Advisors Acquires Additional 3.17% Stake in Cynapsus Therapeutics for USD6.3 Million 16
ex scientia Enters into Research Agreement with Sunovion Pharma 17
Sunovion Pharma Enters Into Agreement With Afraxis To Discover CNS Drugs 18
PsychoGenics Extends Drug Discovery Agreement with Sunovion Pharma 19
Prasco Labs Enters into Distribution Agreement with Sunovion Pharma for Xopenex 20
Angelini Enters into Licensing and Distribution Agreement with Sunovion Pharma 21
Sunovion Pharma Enters into Licensing Agreement with Novartis 22
Cynapsus Therapeutics Enters into Licensing Agreement with MonoSol Rx 23
Cynapsus Therapeutics Raises USD72.5 Million in Public Offering of Shares 24
Cynapsus Therapeutics Raises USD16.6 Million in Private Placement of Shares 26
Cynapsus Therapeutics Completes Public Offering Of Units For US$22.8 Million 28
Cynapsus Therapeutics Completes Second Tranche Of Private Placement Of Units For US$1.3 Million 29
Cynapsus Therapeutics Completes Private Placement Of Units For US$1 Million 31
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.2 Million 32
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.1 Million 33
Cynapsus Therapeutics Completes Additional Public Offering Of Series E Debentures Due 2013 For US$1.1 Million 34
Sunovion Pharma to Divest US Rights of Ciclesonide Products to Covis Pharma 36
Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 37
Sunovion Pharma Acquires Cynapsus Therapeutics for up to USD635 Million 38
Sunovion Pharma Completes Acquisition Of Elevation Pharma For Up To US$430 Million 40
Sunovion Pharmaceuticals Inc, Key Competitors 42
Sunovion Pharmaceuticals Inc, Key Employees 43
Sunovion Pharmaceuticals Inc, Other Locations 44
Sunovion Pharmaceuticals Inc, Subsidiaries 44

List of Figures
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sunovion Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Sunovion Pharmaceuticals Inc：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Oxford Nanopore Technologies Ltd：企業の戦略的SWOT分析
    Oxford Nanopore Technologies Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Societe Nationale d’Electrolyse et de Petrochimie SA (SNP)：企業の財務・戦略的SWOT分析
    Societe Nationale d'Electrolyse et de Petrochimie SA (SNP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the compa …
  • Serica Energy Plc：企業のM&A・事業提携・投資動向
    Serica Energy Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Serica Energy Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Alitair Pharmaceuticals Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Alitair Pharmaceuticals Inc (Alitair) is a pharmaceutical company that provides orphan drugs and medicine products. The company provides orphan drug products and RX and OTC cough and cold products. It offers orphan drug products such as ALT and oral drugs that are widely used to treat variou …
  • Flint Group：企業の戦略・SWOT・財務分析
    Flint Group - Strategy, SWOT and Corporate Finance Report Summary Flint Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Cinkarna Celje d.d. Celje (CICG)：企業の財務・戦略的SWOT分析
    Cinkarna Celje d.d. Celje (CICG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • JXTG Holdings Inc (5020)：企業の財務・戦略的SWOT分析
    JXTG Holdings Inc (5020) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • VMware, Inc.：企業の戦略・SWOT・財務分析
    VMware, Inc. - Strategy, SWOT and Corporate Finance Report Summary VMware, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • DRB-HICOM Defense Technologies Sdn Bhd：企業の戦略・SWOT・財務情報
    DRB-HICOM Defense Technologies Sdn Bhd - Strategy, SWOT and Corporate Finance Report Summary DRB-HICOM Defense Technologies Sdn Bhd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Esperion Therapeutics Inc (ESPR)-製薬・医療分野：企業M&A・提携分析
    Summary Esperion Therapeutics Inc (Esperion) is a pharmaceutical company that develops and commercializes oral therapies to treat patients with elevated low-density lipoprotein cholesterol (LDL-C). The company’s lead product candidate, Bempedoic acid, an ATP-citrate lyase inhibitor which is in Phase …
  • Aminex PLC (AEX)：企業の財務・戦略的SWOT分析
    Summary Aminex plc (Aminex) is an oil and gas company that explores, develops and produces oil and gas reserves in Africa. The company provides assets such as Valeni field and Viktorovka field in Moldova; West Esh el Mellaha-2 in Egypt; and Kiliwani North development, Nyuni exploration and Ruvuma ex …
  • Synthetic Biologics Inc (SYN)：企業の財務・戦略的SWOT分析
    Summary Synthetic Biologics Inc (Synthetic Biologics), formerly Adeona Pharmaceuticals Inc is a clinical company that develops novel therapeutics to treat gut microbiome. The company’s pipeline products include SYN-004 and SYN-010. Its SYN-010 is a proprietary, modified-release formulation which is …
  • Wacker Chemie AG (WCH)-エネルギー分野：企業M&A・提携分析
    Summary Wacker Chemie AG (Wacker) develops, manufactures, and markets various chemical and semiconductor materials. It offers a range of silicone fluids and emulsions, resins, elastomers, sealants and silanes. The company manufactures binders and polymeric additives such as dispersible polymer powde …
  • Bank Of Ireland (Uk) Plc
    Bank Of Ireland (Uk) Plc - Strategy, SWOT and Corporate Finance Report Summary Bank Of Ireland (Uk) Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Meggitt Plc (MGGT)：企業の財務・戦略的SWOT分析
    Meggitt Plc (MGGT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Novartis Institutes for BioMedical Research Inc-製薬・医療分野：企業M&A・提携分析
    Summary Novartis Institutes for BioMedical Research Inc (NIBR), a subsidiary of Novartis AG is a medical research institute that offers treatment research and development programs. The institute offers clinical research services in areas of immuno-oncology, oncology, neuroscience, cardiovascular and …
  • LRAD Corporation：戦略・SWOT・企業財務分析
    LRAD Corporation - Strategy, SWOT and Corporate Finance Report Summary LRAD Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Shree Renuka Sugars Ltd (RENUKA)：企業の財務・戦略的SWOT分析
    Shree Renuka Sugars Ltd (RENUKA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Glanbia Nutritionals Inc-製薬・医療分野：企業M&A・提携分析
    Summary Glanbia Nutritionals Inc (Glanbia Nutritionals) is a global provider of nutritional ingredients, functional ingredients, and customized premix solutions. The company manufactures and markets customized micronutrient blends, vitamins, minerals, amino acids, colors and specialty ingredients. T …
  • Avivagen Inc (VIV)：企業の財務・戦略的SWOT分析
    Summary Avivagen Inc (Avivagen), formerly Chemaphor Inc is a biotechnology company that provides drug development and animal healthcare products. The company develops science-based, natural health products for animals. It operates through divisions including companion animal health, food animal heal …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆